Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Long processing times often stem from underwriting and documentation checks. We explain the common causes and how to minimize delays.
26,998 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A Washington nonprofit filed a federal lawsuit this week to stop the blue repainting of the Lincoln Memorial Reflecti...
Regulatory pressure around UnitedHealth shifts attention to two defensible, cash-generating stocks with strong divide...
Six ETFs now cover the entire grid-resilience thesis, from hardware and software to infrastructure and energy metals,...
As market focus shifts away from growth labels, three legacy automakers stand out for retirees seeking cash flow and ...
Amazon’s cloud powerhouse AWS posted its strongest growth in more than three years, as AI infrastructure investments ...
A Houston-area couple retires at 65 with $7,400 in gross monthly income. After federal taxes, Medicare premiums, and ...
Investors are watching Duluth Trading closely as the Q1 2026 earnings cycle begins. This in-depth look breaks down wh...
Avalanche Treasury Co. (AVAT) opened at $2.99 and closed at $1.85 on its Nasdaq debut, a 38% drop. Here’s what invest...
Investors greeted a policy-driven pact between Apple and Intel, sending intel shares leap after the announcement and ...
Semiconductors led by the SMH and SOXX pulled back sharply, triggering fresh talk of a buyable dip. Famous tech inves...
A wave of quantum funding is moving beyond labs to big-name backers. BlackRock, Nvidia, and Temasek are leading a sur...